Zanidatamab, a bispecific HER2-targeted antibody, delivered clinically meaningful and durable responses for patients with HER2-positive biliary tract cancer (BTC), according to final results from the HERIZON-BTC-01 clinical trial. In this clinical trial, zanidatamab demonstrated an objective response rate of 41.3% and a median duration of response of 15.5 months, while patients whose tumors showed strongest levels of HER2 overexpression experienced even greater benefit – a 51.6% response rate and a median duration of response of 18.1 months Initial trial results were first reported in June 2023. The trial was led by Shubham Pant, M.D., professor of Gastrointestinal Medical Oncology and Investigational Cancer Therapeutics.
“The observed objective response rate, prolonged duration of response, and consistent activity in IHC3+ tumors underscores HER2 as a valid therapeutic target in biliary tract cancer and support the emerging role of zanidatamab in the treatment paradigm,” Pant said.